Jaan-Olle Andressoo

Jaan-Olle Andressoo

Principal Researcher
Visiting address: Neo, Blickagången 16, 14151 Huddinge
Postal address: H1 Neurobiologi, vårdvetenskap och samhälle, H1 Neurogeriatrik Andressoo, 171 77 Stockholm
Part of:

About me

  • CURRENT POSITIONS
    • Assistant Professor, Department of Neurobiology, Care Sciences and
    Society, Karolinska Institutet, Sweden
    • Associate Professor, Translational Neuroscience, Faculty of Medicine,
    University of Helsinki, Finland
    PUBLICATIONS
    https://www.ncbi.nlm.nih.gov/pubmed/?term=andressoo [1]
    • 2017-2022 Nominee of European Research Council (ERC) Consolidator Grant
    • 2017-2022 Nominee of Center of Innovative Medicine Young Investigator
    Grant at Karolinska Institutet, Stockholm
    • 2010-2015 Academy of Finland Research Fellow – the most prestigious
    start-up package for early and mid-stage scientists in Finland
    • 2005-2008 Academy of Finland post-doctoral Fellow – the most
    prestigious post-doctoral grant in Finland
    • 2009 Docent (Adj. Prof.) of Genetics, University of Helsinki (UH),
    Finland
    • 2004 PhD, Erasmus Medical Center, Department of Cell Biology and
    Genetics, Erasmus University, Rotterdam, The Netherlands, Prof Jan H.J.
    Hoeijmakers
    • 1991-1998 Undergraduate studies of Biology, University of Tartu, Estonia
    PREVIOUS POSITIONS
    • Sabbatical year 03.2017 – 12.2017 - Visiting Associate Professor in
    Neurobiology at the Department of Psychiatry, Columbia University, New
    York, USA. Host: Prof David Sulzer
    • 09.2016-08.2017 - Associate Professor, Cell and Tissue Engineering,
    University of Tampere, Finland
    • 2010 – 2017 Principal Investigator, Institute of Biotechnology,
    University of Helsinki, Finland
    • 2010-2015 Academy of Finland Research Fellow (PI) at the Institute of
    Biotechnology (BI), University of Helsinki (UH), Finland
    • 2008-2010 Senior Postdoctoral Associate (Mart Saarma’s group) at the
    BI, UH, Finland
    • 2005-2008 Academy of Finland Post-doctoral Research Fellow (Mart
    Saarma’s group), at the BI, UH, Finland
    • 2004-2005 Post-doctoral researcher at Prof Jan Hoeijmakers laboratory,
    Erasmus Medical Center, Department of Cell Biology and Genetics, Erasmus
    University, Rotterdam, The Netherlands
    • 1999-2004 PhD studies at Prof Jan Hoeijmakers laboratory, Erasmus
    Medical Center, Department of Cell Biology and Genetics, Erasmus University,
    Rotterdam, The Netherlands
    • 1993-1999 Junior scientist in Prof Toivo Maimets laboratory at the
    Institute of Molecular and Cellular Biology, University of Tartu, Estonia
    [1] https://www.ncbi.nlm.nih.gov/pubmed/?term=andressoo

Research

  • Our laboratory’s goal is to develop novel therapeutic approaches by
    fine-tuning the expression of a gene selectively in cells in which the gene
    is normally expressed. We have generated the first proof-of-concept data
    showing that such an approach is technically feasible, can provide new
    information on gene function and may allow development of new treatment
    modes.
    Specifically, we manipulate the 3’UTR of target genes which allows us to
    control endogenous gene expression in cells that naturally express the gene
    of interest.
    At Karolinska Institutet our laboratory’s primary goal is to develop
    treatment for currently incurable neurodegenerative diseases such as
    Alzheimer’s disease. Recently, our laboratory received funding from Center
    of Innovative Medicine (CIMED) with the focus on generating better mouse
    models and treatment modes for Alzheimer’s disease. More specifically, we
    aim to study how increase in endogenous beta-amyloid impacts Alzheimer’s
    disease etiology and investigate how upregulation of endogenous genes which
    control proteostasis, mitochondrial and neurotrophic functions impact AD
    etiology in mice. My laboratory at the University of Helsinki Faculty of
    Medicine, recently supported with ERC CoG and several other grants, focuses
    on similar objectives for Parkinson’s disease.
    Our laboratory uses genetic engineering in mouse models accompanied with
    analysis at the molecular, cellular, tissue, behavioral and recently -
    electrophysiological level. For enhancing power of our genetic experiments we
    are, as a new opening, currently implementing alternative model organisms
    such as zebrafish.
    As a serendipitous spin-off from our genetic experiments with neurotrophic
    factor GDNF signaling system we have also generated a new mouse model for
    long-segment Hirschsprung’s disease, which allows characterization and
    treatment discovery in postnatal mice. We have also generated a new mouse
    mouse model for Congenital Anomalies of the Kidney and Urinary Tract (CAKUT)
    which we currently analyze in collaboration with Dr Satu Kuure’s group at
    the University of Helsinki.

Teaching

  • 98h of lecturing experience since 2007 at the University of Helsinki,
    Finland and at Tallinn University of Technology, Estonia.

Articles

All other publications

News from KI

Events from KI